After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ:NVAX) can now heave a sigh of relief.
Adcom Unanimously Backs Novavax: FDA's Vaccines and Related Biological Products Advisory Committee that reviewed the Gaithersburg, Maryland-based company's biologic license application decided to unanimously recommend approval of the first protein-based vaccine candidate in the U.S.
